Asymmetric dimethylarginine(ADMA)is a nitric oxide synthase(NOS)inhibitor.ADMA is formed by methylation of L-arginine residues.It innbits the formation of vasoactive substances(nitric oxide),resulting in endothelial dysfunction and vaseular diseases.A number of studies have suggested that ADMA may be a risk factor for stroke.The expression of ADMA increases significantly in patients with hyperhomocysteinemia,carotid stenosis and cardiovascular disease.

The incidence of early neurological deterioration of acute ischemic stroke is higher and the clinical prognosis is poor.There are no effective prevention and treatment measures yet.The prognosis may be improved if early predicts by serum biomarkers and actively manages.This article reviews the serum biomarkers of early neurological deterioration in ischemic stroke.

Intracranial atherosclerotic stenosis mostly occurs in Asians,blacks and Hispanicsis,which is the most important reason for the occurrence and recurrence of ischemic stroke.The current studies mainly concentrate on the aspect of the relationship between the intracranial atherosclerotic stenosis and the traditional risk factors.With the development of genetic technology,the relationship between the genetic factors and intracranial atherosclerotic stenosis has also received increasing attention.This article reviews the advances in research on the traditional risk factors for intraeranial atherosclerotic stenosis and genetic research.

The mechanisms underlying early neurological deterioration (END) after ischemic stroke are not clear.There are no reliable predictive factors and effective preventive measures for END.The glutamatemediated excitotoxicity plays a very important role in the cascade reaction of ischemic events.High level of glutamate in plasma is one of the important predictors for END.Studies have shown that the polymorphism in the promoter of the excitatory amino acid transporter-2 gene is a potential cause for individual susceptibility to END.Some therapeutic strategies of interrupting the glutamatergic pathways may be as the strategies of intervention END.

In 1990,the concept of microembolic signal (MES) was put forward by Spencer et al for the first time.In 1995,the expert consensus of diagnostic criteria for MES was published in Stroke.Since then,microemboli detection had been widely used as the intraoperative monitoring indicators in cerebral angiography,intravascular stenting,and carotid endarterectomy for the prevention of thrombotic events in patients with carotid artery stenosis.In recent years,microemboli detection has become an evaluation means for carotid stenosis surgery,interventional treatment and drug antithrombotic therapy.

Local intra-arterial thrombolysis has better efficacy in treating acute ischemic stroke, including cardiogenic embolism, and the safety of combined intravenous and intra-arterial thrombolysis is higher. Recent studies have suggested that the combination of angioplasty and local intra-arterial thrombolysis plays an important role in the treatment of acute ischemic stroke during an acute emergency.

The epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases have close connection with the initiation, progression and progn osis of various malignancies. Recently, several approaches such as monoclonal an tibodies, bispecific antibodies, low molecular weight tyrosine kinase inhibitors and gene therapy targeting the EGFR family of receptors for anti-tumor therapy have been developed, some of which are currently undergoing clinical trials. Th ey are generally well tolerated, and have shown encouraging clinical efficacy in a variety of tumor types.

Current anti-hepatoma agents in clinical aplication have not been proved to be satisfactory. The major obstacles are low efficacy, toxicity, and drug resistance. Identifying new drug targets and discovering new agents accordin gly with high efficacies and low toxicities have become the key part of the solu tion. Recent studies have shown that hyper-methylation of tumor suppressor gene s, interaction between hepatocyte growth factor and its receptor, vascular endothelial growth factor and its receptor, as well as cyclooxygenase-2 might be potential targets for hepatomachemotherapy. Indeed, agents acting on these targets have shown to be effective. In addition, other agents such as As 2O 3 have also shown th eir activities against hepatoma.

The challenge of the emergence of drug-resistant influenza strains, which is caused by wide spread utilization of direct-acting antivirals (DAAs), accelerates the research and exploration towards host targeted agents. In contrast to DAAs targeting viral replication components, host targeted agents, which regulate host factors and pathways linked to viral replication, can interfere the replication of influenza. Additionally, the innate immune system is activated by influenza during the early stage of infection, so manipulating the innate immune response may prevent the viral infection. However, the excessive inflammatory response induced at the late phase of influenza infection would lead to severe tissue injures. Thus, it is very important to explore drugs with anti-inflammatory actions to suppress these immune imbalances and tissue injures. Here we overview the current progresses about host targets related to anti-influenza drugs.

The infection of chronic refractory wound is related with bacterial biofilm .How to prevent and treat bacterial bio-film and its related damage has been a hot topic in current studies .This article provides a review on chronic wound biofilm on clinical diagnosis techniques , diagnostic criteria , bacteria identification outcomes and influencing factors .